Literature DB >> 25302138

Anti-Angiogenic Drugs: Involvement in Cutaneous Side Effects and Wound-Healing Complication.

Richard J Bodnar1.   

Abstract

Significance: The uses of anti-angiogenic drugs have not only made an impact on the battle to eliminate cancer but are also responsible for a number of medical complications. The long-term use of these drugs has increased the spectrum and incidence of cutaneous side effects and wound-healing complications. It is, therefore, necessary to understand the overall impact that these drugs have on patient care. Recent Advances: This review highlights the role of vascular endothelial growth factor and fibroblast growth factor in angiogenesis and wound healing and looks at how angiogenic inhibitors promote wound-healing complications. Critical Issues: With an increased use of anti-angiogenic drugs for the treatment of various cancers and ocular diseases, there is an increased need for clinicians to define the risks and to optimize the usage of these drugs to reduce the incidence of cutaneous side effects and wound-healing complications. In addition, awareness is needed when treating patients on anti-angiogenic drugs so as not to exacerbate potential wound-healing complications when performing surgical procedures. Future Directions: Clinicians and surgeons will need to develop management guidelines to optimize patient care to reduce the risk of morbidity. When performing a surgical procedure, the impact of adverse effects from the use of anti-angiogenic drugs should be considered to ensure the welfare of the patient. In addition, the development of more specific inhibitors is necessary to reduce target effects to reduce the occurrence of adverse effects.

Entities:  

Year:  2014        PMID: 25302138      PMCID: PMC4183909          DOI: 10.1089/wound.2013.0496

Source DB:  PubMed          Journal:  Adv Wound Care (New Rochelle)        ISSN: 2162-1918            Impact factor:   4.730


  53 in total

Review 1.  Angiogenesis and signal transduction in endothelial cells.

Authors:  R Muñoz-Chápuli; A R Quesada; M Angel Medina
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

Review 2.  Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.

Authors:  Christopher Lieu; John Heymach; Michael Overman; Hai Tran; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2011-09-27       Impact factor: 12.531

Review 3.  FGF receptor inhibitors: role in cancer therapy.

Authors:  Gennaro Daniele; Jesus Corral; L Rhoda Molife; Johann S de Bono
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 4.  Regulation of angiogenesis by macrophages, dendritic cells, and circulating myelomonocytic cells.

Authors:  Zhao Ming David Dong; Alfred C Aplin; Roberto F Nicosia
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

5.  The microcirculation in acute murine cutaneous incisional wounds shows a spatial and temporal variation in the functionality of vessels.

Authors:  Joanne E Bluff; Siobhan O'Ceallaigh; Sharon O'Kane; Mark W J Ferguson; Grenham Ireland
Journal:  Wound Repair Regen       Date:  2006 Jul-Aug       Impact factor: 3.617

6.  Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells.

Authors:  Sirin A I Adham; Ifat Sher; Brenda L Coomber
Journal:  Lab Invest       Date:  2010-03-01       Impact factor: 5.662

7.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

Review 8.  A practical guide to wound healing.

Authors:  Jeffrey E Janis; Robert K Kwon; Donald H Lalonde
Journal:  Plast Reconstr Surg       Date:  2010-06       Impact factor: 4.730

Review 9.  Intricacies of bevacizumab-induced toxicities and their management.

Authors:  Sarah M Gressett; Sachin R Shah
Journal:  Ann Pharmacother       Date:  2009-03-03       Impact factor: 3.154

10.  The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing.

Authors:  John B Christoforidis; Jillian Wang; Angela Jiang; James Willard; Cedric Pratt; Mahmoud Abdel-Rasoul; Sashwati Roy; Heather Powell
Journal:  Clin Ophthalmol       Date:  2013-01-24
View more
  9 in total

1.  The transcription factor ZFHX3 is crucial for the angiogenic function of hypoxia-inducible factor 1α in liver cancer cells.

Authors:  Changying Fu; Na An; Jinming Liu; Jun A; Baotong Zhang; Mingcheng Liu; Zhiqian Zhang; Liya Fu; Xinxin Tian; Dan Wang; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2020-04-10       Impact factor: 5.157

2.  Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial.

Authors:  Hui-Chuan Sun; Xiao-Dong Zhu; Jian Zhou; Qiang Gao; Ying-Hong Shi; Zhen-Bing Ding; Cheng Huang; Shuang-Jian Qiu; Ning Ren; Guo-Ming Shi; Jian Sun; Qing-Hai Ye; Xiao-Wu Huang; Xin-Rong Yang; Jia Fan
Journal:  Ann Transl Med       Date:  2020-10

3.  In vivo and In vitro effects of ethanolic extract of Trigonella foenum-graecum L. seeds on proliferation, angiogenesis and tube formation of endothelial cells.

Authors:  Mozhdeh Iranmanesh; Reza Mohebbati; Fatemeh Forouzanfar; Mostafa Karimi Roshan; Ahmad Ghorbani; Mohammad Jalili Nik; Mohammad Soukhtanloo
Journal:  Res Pharm Sci       Date:  2018-08

Review 4.  Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health.

Authors:  Nicolae Ghinea
Journal:  Diseases       Date:  2021-04-10

5.  Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation?

Authors:  Ilias Kounis; Maïté Lewin; Astrid Laurent-Bellue; Edoardo Poli; Audrey Coilly; Jean-Charles Duclos-Vallée; Catherine Guettier; René Adam; Jan Lerut; Didier Samuel; Olivier Rosmorduc
Journal:  Ther Adv Med Oncol       Date:  2022-03-23       Impact factor: 8.168

6.  Renal cell carcinoma with early skin metastasis and partial response on tyrosine kinase inhibitor: A case report.

Authors:  Agus Rizal Ardy Hariandy Hamid; Reginald Rustandi; Sahat Matondang; Meilania Saraswati; Lenny Sari; Sonar Soni Panigoro
Journal:  Int J Surg Case Rep       Date:  2022-04-05

Review 7.  Restorative oncodermatology: Diagnosis and management of dermatologic sequelae from cancer therapies.

Authors:  Anthony M Rossi; Brian P Hibler; Cristian Navarrete-Dechent; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2020-08-08       Impact factor: 15.487

Review 8.  New Cancer Therapies: Implications for the Perioperative Period.

Authors:  Tayab Andrabi; Katy E French; Muzaffar H Qazilbash
Journal:  Curr Anesthesiol Rep       Date:  2018-12-06

Review 9.  MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential.

Authors:  Behnaz Lahooti; Sagun Poudel; Constantinos M Mikelis; George Mattheolabakis
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.